Keros Therapeutics (KROS) Non-Current Assets (2019 - 2025)

Keros Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $22.6 million for Q4 2025.

• Quarterly Non-Current Assets fell 16.32% year-over-year to $22.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $95.5 million (down 3.78% YoY) and the FY2025 annual result came in at $22.6 million, down 16.32% from the prior year.
• Non-Current Assets was $22.6 million for Q4 2025 at Keros Therapeutics, down from $23.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $27.2 million in Q3 2024 and bottomed at $1.7 million in Q1 2021.
• A 5-year average of $16.5 million and a median of $22.1 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets soared 466.39% — and 2025, when it declined 16.32%.
• Keros Therapeutics' Non-Current Assets stood at $3.8 million in 2021, then surged by 451.4% to $21.0 million in 2022, then rose by 8.18% to $22.7 million in 2023, then advanced by 18.74% to $27.0 million in 2024, then retreated by 16.32% to $22.6 million in 2025.
• Business Quant data shows KROS's Non-Current Assets at $22.6 million in Q4 2025, $23.5 million in Q3 2025, and $24.4 million in Q2 2025.